Related Experiment Videos
Secondary prevention with calcium antagonists after acute myocardial infarction
1Department of Cardiology, Hvidovre University Hospital, Denmark.
Insights
Calcium antagonists like nifedipine, diltiazem, and verapamil show varied effects in secondary prevention after myocardial infarction. Verapamil and diltiazem offer benefits, especially in patients without heart failure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Nifedipine, diltiazem, and verapamil are calcium antagonists.
- These drugs show comparable effects in preventing myocardial damage during ischemia.
- However, their efficacy in secondary prevention after acute myocardial infarction differs significantly.
Purpose of the Study:
- To compare the effects of nifedipine, diltiazem, and verapamil in secondary prevention trials after acute myocardial infarction.
- To evaluate the differences in clinical findings between these three drugs and explain the variations.
Main Methods:
- Analysis of secondary prevention trials involving nifedipine, diltiazem, and verapamil post-myocardial infarction.
- Stratification of results based on patient history of heart failure before randomization.
Main Results:
- Nifedipine demonstrated no significant effect on reinfarction or mortality.
- Diltiazem showed no overall effect but reduced cardiac events in patients without prior heart failure, while increasing events in those with heart failure.
- Verapamil prevented major adverse events, with the most significant benefit observed in patients without pre-existing heart failure. Verapamil did not adversely affect patients with heart failure.
Conclusions:
- The clinical outcomes of nifedipine, diltiazem, and verapamil in secondary prevention after myocardial infarction are distinct.
- Verapamil and diltiazem offer significant benefits, particularly in patients without heart failure.
- Patient's heart failure status is a critical factor in determining the efficacy and safety of these calcium antagonists.
Abstract:
Experimental studies have demonstrated that the 3 calcium antagonists nifedipine, diltiazem, and verapamil have a comparable effect in the prevention of myocardial damage during ischaemia. Secondary prevention trials after acute myocardial infarction, which aimed at improving survival and preventing reinfarction, nevertheless demonstrated pronounced differences between the 3 drugs. Nifedipine had no effect on reinfarction or death. Diltiazem had no overall effect but prevented first reinfarction or cardiac death (cardiac events) in patients without heart failure, and increased cardiac events in patients with heart failure before randomisation. Verapamil prevented first reinfarction or death (major events); the most pronounced effect was found in patients without heart failure before randomisation. Verapamil did not have detrimental effects in patients treated for heart failure before randomisation. Differences between trials and between drugs explaining the different clinical findings are evaluated.